Recent results just published by WELBIO Investigator Stefan Constantinescu (UCLouvain) and his team in the journal Blood report a novel mechanism by which that a class of mutants in the chaperone calreticulin induce blood cancers denoted as myeloproliferative neoplasms.
A newly discovered bacterium has been named after our research institute. The human gut microbe was discovered during a project led by Patrice Cani (WELBIO & FNRS investigator at UCLouvain), who proposed the scientific name Dysosmobacter welbionis
Patrice Cani, WELBIO investigator at University of Louvain (UCLouvain), and his team conducted the first pilot study in humans to observe the impact of the bacteria Akkermansia, particularly on the reduction of cardiovascular risk factors. The results are published in the scientific journal Nature Medicine. The bacterium significantly limits the increase of several risk factors for cardiovascular diseases.
WELBIO and the FNRS just selected 14 new life sciences research projects (on 65 proposals). These very high-level projects will benefit from a total budget of 7.5 millions of euros over a 2-year period. At the same time, 14 ongoing projects were renewed for a second 2-year period. All in all, nearly 15 millions of euros will be invested by the Walloon Region in very ambitious projects to boost basic research in the strategic axis of life sciences.
Decio L. Eizirik, Welbio Researcher at the ULB and Director of the ULB Center for Diabetes, has been appointed for a prestigious Visiting Professorship at the Danish Diabetes Academy (DDA). Denmark is a leading country in diabetes research, and the Danish Diabetes Academy is an international reference in the field.
Here is the annual report 2018 of WELBIO. It provides you with information on our projects portfolio, on WELBIO investigators, their publications and the awards they received, on technology transfer progresses as well as the financial report.
The research team of Isabelle Migeotte, WELBIO investigator at the ULB, describes major differences in mesoderm cells when they migrate in extra-embryonic vs. embryonic regions, providing a molecular framework to understand how cells with distinct fates adapt to, and probably modify, their tridimensional environment. The results of this study have been published in eLife.
The 2019 FRFS-WELBIO call for projects is open. Applications to be submitted and validated by the principal investigator on the FRS-FNRS Semaphore platform before Friday 15 March 2019 14:00.
The Francqui Foundation aims at “furthering the development of higher education and scientific research in Belgium". On the proposal of Universities, the Foundation grants each year a number of “Francqui Chairs” for inviting a Professor from another Belgian University to provide 10 h of specialized teaching. Prof. Cédric Blanpain, WELBIO investigator at the Université libre de Bruxelles, Director of the Laboratory Stem Cell and Cancer, will be holding the Collen - Francqui Chair 2018-2019 at the Faculty of Medicine and Pharmacy of the Vrije Universiteit Brussel (VUB). The inaugural lecture will take place on 22 February 2019. It will focus on Mechanisms regulating pluripotent stem cells.
In a study published in Nature Chemical Biology Abel Garcia-Pino WELBIO investigator at the Université libre de Bruxelles and colleagues from the Cellular and Molecular Microbiology team from the ULB provided for the first time experimental evidence to a long held hypothesis on small bacterial operons encoding a toxin and a corresponding neutralizing antitoxin, so-called toxin-antitoxins (TA) modules: antitoxins act as chaperones that can trap toxins while they are produced by the ribosome.
A research, started in 2010 and financed by the WELBIO-FNRS, the Fonds Baillet-Latour and an ERC, has just been published in Nature Communications. Prof. Patrice Cani (WELBIO investigator at Louvain Drug Research Institute, UCLouvain) and his team, in association with Canadian, Italian, French and Dutch researchers, were able to target a dysfunctional enzyme in overweight or obese subjects, therefore the message “I am not hungry anymore” is no more transmitted to the brain.
In a study led by Prof. Emile Van Schaftingen (WELBIO investigator at Université Catholique de Louvain), scientists showed that 2 rare genetic diseases leading to an abnormally low concentration of neutrophils in the blood (neutropenia) are due to a lack of metabolic repair which causes the accumulation of a toxic product. The results of this study have been published in PNAS.